Premium
Inhibitory killer cell immunoglobulin‐like receptor ( iKIR ) mismatches improve survival after T‐cell‐repleted haploidentical transplantation
Author(s) -
BastosOreiro Mariana,
Anguita Javier,
MartínezLaperche Carolina,
Fernández Lucía,
Buces Elena,
Navarro Almudena,
Pascual Cristina,
PérezCorral Ana,
Balsalobre Pascual,
Muñoz Cristina,
Kwon Mi,
Serrano David,
PerezMartinez Antonio,
Buño Ismael,
Gayoso Jorge,
DíezMartín José Luís
Publication year - 2016
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12616
Subject(s) - hematopoietic stem cell transplantation , transplantation , receptor , lymphoma , immunology , medicine , t cell , antibody , oncology , immune system
Alloreactivity triggered by interaction between killer cell immunoglobulin‐like receptors ( KIR s) and natural killer ( NK ) cells plays a role in the graft‐versus‐tumor effect after hematopoietic stem cell transplantation ( SCT ). Our aim in this study was to evaluate this role in the setting of T‐cell‐repleted haploidentical SCT with postinfusion high‐dose cyclophosphamide ( PT ‐Cy). We included 33 patients. Among patient–donor pairs with at least 1 inhibitory KIR ( iKIR ) gene mismatch, event‐free survival ( EFS ) and cumulative incidence of relapse 1 year after transplant were significantly better (85% vs. 37% [ P = 0.008] and 18% vs. 46% [ P = 0.041], respectively). A subanalysis in 12 patients with Hodgkin's lymphoma ( HL ) showed an improvement in EFS 1 year after transplant in those patients with KIR ligand mismatch (100% vs. 25%, P = 0.012), although overall survival ( OS ) was not affected (85% vs. 80%, P = 0.2). Eight of 12 patient–donors pairs presented iKIR mismatches. Of note, this outcome was better in the small subgroup, both for EFS (100% vs. 25%, P = 0.012) and for OS (100% vs. 37%, P = 0.004). Our data suggest that in the setting of T‐cell‐repleted haploidentical SCT with PT ‐Cy, iKIR mismatch is associated with improved survival, with particularly good results for both iKIR and KIR ligand mismatches in patients with HL.